Bolzon Bradley J PhD 4

Accession 0000899243-21-026801

CIK 0001674416other

View on SEC.gov Company Profile

Filed

Jun 29, 8:00 PM ET

Accepted

Jun 30, 6:41 PM ET

Size

58.2 KB

Accession

0000899243-21-026801

Insider Transaction Report

Form 4

Period: 2021-06-28

CRISPR Therapeutics AGCRSP

Bolzon Bradley J PhD

Director

Transactions

Other
Common Shares
2021-06-28+6,018→ 6,018 total(indirect: See Footnote)
Sale
Common Shares
2021-06-29$151.24/sh−6,646$1,005,162→ 1,200 total
Other
Common Shares
2021-06-28+158,522→ 158,522 total(indirect: See Footnote)
Other
Common Shares
2021-06-28−158,522→ 0 total(indirect: See Footnote)
Other
Common Shares
2021-06-28+2,378→ 81,452 total(indirect: See Footnote)
Other
Common Shares
2021-06-28−12,189→ 6,268 total(indirect: See Footnote)
Other
Common Shares
2021-06-28−84,085→ 0 total(indirect: See Footnote)
Other
Common Shares
2021-06-28−27,861→ 16,434 total(indirect: See Footnote)
Other
Common Shares
2021-06-28−615,607→ 104,874 total(indirect: See Footnote)
Other
Common Shares
2021-06-28−6,018→ 0 total(indirect: See Footnote)
Sale
Common Shares
2021-06-29$145.92/sh−1,400$204,284→ 46,136 total
Sale
Common Shares
2021-06-29$147.43/sh−4,780$704,725→ 40,756 total
Sale
Common Shares
2021-06-29$150.49/sh−12,753$1,919,237→ 7,846 total
Sale
Common Shares
2021-06-29$152.42/sh−1,200$182,906→ 0 total
Other
Common Shares
2021-06-28+27,716→ 27,716 total
Other
Common Shares
2021-06-28−3,650→ 622 total(indirect: See Footnote)
Other
Common Shares
2021-06-28−366,084→ 215,915 total(indirect: See Footnote)
Other
Common Shares
2021-06-28+79,074→ 79,074 total(indirect: See Footnote)
Other
Common Shares
2021-06-28−11,011→ 5,614 total(indirect: See Footnote)
Other
Common Shares
2021-06-28+2,633→ 84,085 total(indirect: See Footnote)
Other
Common Shares
2021-06-28+18,973→ 46,689 total
Other
Common Shares
2021-06-28+847→ 47,536 total
Sale
Common Shares
2021-06-29$146.69/sh−600$88,016→ 45,536 total
Sale
Common Shares
2021-06-29$148.58/sh−12,176$1,809,095→ 28,580 total
Sale
Common Shares
2021-06-29$149.47/sh−7,981$1,192,915→ 20,599 total

Footnotes (35)

[F1]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("VVC IV") to its partners pursuant to a Rule 10b5-1 trading plan.
[F10]These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
[F11]Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.
[F12]Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
[F13]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners pursuant to a Rule 10b5-1 trading plan.
[F14]These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
[F15]Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.
[F16]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") to its partners pursuant to a Rule 10b5-1 trading plan.
[F17]These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
[F18]Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOA.
[F19]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V to its members.
[F2]These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and dispositive power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
[F20]Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V.
[F21]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC CAN") to its partners pursuant to a Rule 10b5-1 trading plan.
[F22]These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. Each of VV V CAN GP and VV V CAN may be deemed to have voting and dispositive power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
[F23]Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC CAN.
[F24]Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
[F25]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V CAN to its partners.
[F26]Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V CAN.
[F27]The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
[F28]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $145.89 to $145.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (28) to this Form 4.
[F29]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $146.00 to $146.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (29) to this Form 4.
[F3]Represents a change in the form of ownership of VV IV by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC IV.
[F30]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $147.01 to $147.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (30) to this Form 4.
[F31]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $148.00 to $148.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (31) to this Form 4.
[F32]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $149.00 to $149.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (32) to this Form 4.
[F33]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (33) to this Form 4.
[F34]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.00 to $151.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (34) to this Form 4.
[F35]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.03 to $152.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (35) to this Form 4.
[F4]Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
[F5]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV IV to its members.
[F6]Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV IV.
[F7]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("VSF IV") to its partners pursuant to a Rule 10b5-1 trading plan.
[F8]These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and dispositive power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
[F9]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners pursuant to a Rule 10b5-1 trading plan.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

CRISPR Therapeutics AG

CIK 0001674416

→

Entity typeother

Related Parties

filerCIK 0001354345

Filing Metadata

Form type: 4
Filed: Jun 29, 8:00 PM ET
Accepted: Jun 30, 6:41 PM ET
Size: 58.2 KB

View on SEC.gov